Agenda 议程

Day One

08.20  Registration

09.00  Chairperson’s Opening Speech

09.15  Update on PRC Patent Law and Pharma & Biotech Patent Examination

中国专利法最新动态及医药生物审查实务

Qingkui ZHANG, Director General, The Pharma and Biological Examination Department, SIPO

张清奎，医药生物发明审查部部长，国家知识产权局 

10.00   IP Information Search and Analysis for Generic Drug R&D and Techniques Innovation

在药品仿制研发与工艺创新中的知识产权信息检索与分析

Limin NIU, Senior Manager, Huake Pharmaceutical Intellectual Property Consultative Center

牛利民，高级经理，华科医药知识产权咨询中心.

10.45  Networking and Refreshment Break

11.15  Recent Litigation Developments in the U.S. Market and Its Relevance on Chinese Enterprise

美国市场中的最新诉讼进展及其对中国企业的影响

David S. Steuer, Partner, Wilson Sonsini Goodrich & Rosati

大卫•S•斯图尔，合伙人，威尔逊•桑西尼•古奇•罗沙迪律师事务所

12.00  Luncheon

13.45  Latest Updates on the Development of Pharma & Biotech Patents Application in China

n Sufficient Disclosure Requirement for Pharmaceutical Patents in China药物专利中的充分公开问题

n Recent Development of Biopharmaceutical Patents in China生物制药领域专利申请的最新进展

Chuanhong LONG, Vice President,  CCPIT Patent and Trademark Law Office

龙传红, 中国贸促会专利商标事务所副所长

14.45    Selecting the Most Commercially Viable Patents in Your IP Portfolio: Understanding What’s on Your R&D Pipeline

Lawrence T. Welch, Assistant General Patent Counsel, Eli Lilly and Company

Lawrence T. Welch，副总专利顾问，全球专利采购政策总监, 美国礼来公司

15.30  Networking and Refreshment Break

16.00  The Patent Risks & Opportunities When Branded Products Go Generic – The Innovator’s Perspective

Peter Dolan, Head of India, China, Japan & Asia Pacific Region Patents, Sanofi-aventis

Peter Dolan，中国，日本，印度及亚太地区专利总监，赛诺菲-安万特

16.45  Chairperson’s Closing Remark

17.30  End of Day One

Day Two

08.30  Morning Refreshment & Coffee

09.00  Chairperson’s Opening Speech

09.10  Cases Study: Judicial Analysis of Critical Legal Issues and Drug Patent Invalidation Litigation

仿制药和生物技术专利诉讼策略与案例分享

Zhipei JIANG, Head of IPR Tribunal (retired), PRC Supreme People’s Court

蒋志培， 前任庭长， 最高人民法院知识产权庭

10.00  Litigation Strategy and Solution on Drug Patent Protection—A Pragmatic Review Based on Latest Juridical Practice

与医药行业发展有关的专利保护实务问题—依据新专利法、司法解释与审判实践

Yongshun CHENG, Director, Beijing Intellectual Property Institute

程永順，主任，北京务实知识产权发展中心

10.45  Networking and Refreshment Break

11.15  Successful Road to US Generic Market – ANDA Paragraph IV Litigation based on Hatch Waxman

James Hurst, Chair of Intellectual Property Practice, Winston & Strawn LLP

吉姆 赫斯特，知识产权业务主席，美国温斯顿律师事务所

12.00  Luncheon

13.45  China Needs to build a Pharma Patent Challenging Mechanism Based on Pro Bono Publico

Chu ZHANG, Director, Center for Intellectual Property Rights Studies(CIPRS), China University of Political Science and Law (CUPL)

14.30  Considering Licensing as a R&D Strategy – From Licensee’s Perspective

专利许可是中国新药发展的重要模式

Allan (Riting) LIU, Senior Special Consultant (former Vice President), Wanbang Biopharmaceuticals Co., Ltd.

刘日廷，高级顾问（副总裁级），万邦生化医药公司

15.15  Networking and Refreshment Break

15.45  Discussion: The Evolving Generics Industry in Asia and Strategic Alliances between Innovators and Generics小组讨论：从亚洲仿制药产业的发展变化看专利药厂和仿制药厂间的战略合作关系

n  What are the key factors to consider when entering the Asian generics market?

n  What are the imperatives for such alliances and what strategic shifts could be expected on this front?

n  China and India—joint effort or rival players?

n  How will the emerging trend of biosimilars change the dynamics of the market?

16.35  Chairperson’s Closing Remark

16.45  End of the Conference

感谢您的关注并期待您的参与！